APA (7th ed.) Citation

M, P., V, S., NC, K., N, J., S, G., V, G., . . . ACB, C. (2023). Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy. Cancer research communications, 3(7), 1378. https://doi.org/10.1158/2767-9764.CRC-23-0111

Chicago Style (17th ed.) Citation

M, Pan, et al. "Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy." Cancer Research Communications 3, no. 7 (2023): 1378. https://doi.org/10.1158/2767-9764.CRC-23-0111.

MLA (9th ed.) Citation

M, Pan, et al. "Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy." Cancer Research Communications, vol. 3, no. 7, 2023, p. 1378, https://doi.org/10.1158/2767-9764.CRC-23-0111.